Vaccines

#Appointment #Cell and gene therapy #Covid-19 #Diversity #HIV #Vaccines

This week in drug discovery (20-24 June)

News round-up by DDW’s Reece Armstrong for 20-24 June. Covid-19 vaccine development and research, gene therapies for dementia and a ‘game-changing’ treatment for HIV are some of the themes of this week’s news round-up. Moderna to set up mRNA vaccine centre in UK  Pharmaceutical company Moderna is to set-up… Read More

#News

#Biopharma #Covid-19 #mRNA #Vaccines

mRNA vaccines – how do we keep up with the new kid on the block? 

By Greg Kulnis  - Vice President, Customer Solutions (Infectious Disease) for Nexelis The Covid-19 pandemic has led to unprecedented collaboration and acceleration in vaccine development. In the past two years, many leading pharmaceutical and biotech companies have shifted their research and development (R&D) focus to tackle the threat of SARS-CoV-2. Read More

#Exclusive Content

#Malaria #Vaccines #World Malaria Day

World Malaria Day – efforts by the pharma industry  

Despite continuous work by the scientific community, malaria remains one of the largest and deadliest diseases on the planet. The disease, which is spread via the bites of female Anopheles mosquitoes, was responsible for 627,000 deaths in 2020, with 95% of those occurring in Africa.    The disease… Read More

#News

#Biopharma #Clinical trial #Covid-19 #Genetics #Vaccines

This week in drug discovery (18-22 April)  

News round-up by DDW’s Reece Armstrong for 18-22 April    Covid-19, the link between ageing and genetic mutations, alongside funding opportunities for drug developers are some of the themes of this week’s news round-up.   1: Researchers shed light on ageing in new… Read More

#News

Vaccine
#Lipids #RNA #Vaccines

eTheRNA Manufacturing launches service for RNA vaccines

Specialist RNA process developer eTheRNA Manufacturing has introduced a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.  This new LNP service uses eTheRNA’s proprietary lipid libraries and formulations to facilitate targeted delivery and… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #Vaccines

Moderna provides a clinical update on Delta variant immunity

Moderna has announced new results from in vitro neutralisation studies of sera from individuals vaccinated with the Moderna Covid-19 vaccine showing activity against variants of SARS-CoV-2. Vaccination with the Moderna Covid-19 vaccine produced neutralising titres against all variants tested, including additional versions of the Beta variant (B.1.351, first identified in… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #mRNA #Pfizer #Vaccines

The human touch: the benefits of real world evidence

Listen to this article on the DDW Podcast: Lu Rahman looks at the growing role of real world evidence and its benefits in the fight against Covid-19. Real world evidence (RWE)  is nothing new. While clinical trials have a significant part to play  - and indeed remain the ultimate standard for… Read More

#Business & Investment #Covid-19 #Editor's Choice #Exclusive Content #News

#Covid-19 #Immunology / Virology & Vaccines #Vaccines

This week in drug discovery (28 June – 2 July)

News round-up by DDW’s Megan Thomas for 28 June – 2 July This week in news The last year and a half has accelerated the virology scene at a pace that was previously unseen, and not exclusively for Covid-19. Vaccines continue to be an unquestionably important part of how we… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Positive new data for J&J Covid vaccine against Delta variant

Johnson & Johnson has announced data that demonstrated its single-shot Covid-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of… Read More

#News #Trending News

#Clinical trials #Immunology / Virology & Vaccines #Malaria #Vaccines

Investigational malaria vaccine gives strong, lasting protection

Two US Phase I clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs—an approach termed chemoprophylaxis vaccination. Read More

#News

#Antibodies #AstraZeneca #Biomedical research #Covid-19 #Immunology / Virology & Vaccines #Pfizer #Vaccines

Covid antibody levels vary according to vaccine type

Two doses of the Oxford-AstraZeneca Covid-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains. These laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre are published… Read More

#Covid-19 #News #Trending News

#Drug delivery #Drug development #Immunology / Virology & Vaccines #mRNA #Vaccines

Sanofi launches dedicated mRNA vaccines centre

Sanofi will invest approximately €400 million annually in a vaccines mRNA Centre of Excellence. The centre will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Public health #Sinovac #Vaccines

Has China approved a Covid-19 vaccine for three year olds?

The New York Times has reported that the Chairman of the Chinese drug maker Sinovac said China had approved the company’s Covid-19 vaccine for children as young as three, which the media outlet explains would make the country the first in the world to endorse a vaccine for children of… Read More

#Covid-19 #News #Trending News

#Drug delivery #Drug development #Immunology / Virology & Vaccines #mRNA #Vaccines

Samsung Biologics adds mRNA vaccine manufacturing to its services

Samsung Biologics, a CDMO, plans to add mRNA vaccine drug substance (DS) manufacturing capability to its current facility in Songdo, ready for cGMP operations within early 2022. mRNA has been the technology of choice for many Covid-19 vaccines due to its characteristics of safety and fast scalability in manufacturing. “We… Read More

#News

#Clinical trials #Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Janssen single-dose COVID-19 vaccine approved for use in the UK

Johnson & Johnson has announced topline efficacy and safety data from the Phase III ENSEMBLE clinical trial, demonstrating that the investigational single-dose Covid-19 vaccine in development at Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468… Read More

#Covid-19 #News #Trending News

#Clinical research #Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Vaccines

Positive interim Phase II results for GSK Medicago Covid-19 vaccine

Medicago and GlaxoSmithKline (GSK) have reported positive interim Phase II clinical trial safety and immunogenicity data for Medicago’s plant-derived Covid-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant. These results are part of the ongoing Phase II/III study and reiterate the promising profile observed during Phase… Read More

#Covid-19 #News